Clinical Trials Browser

Phase 3 × Has results × Trastuzumab × Clear all

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Breast

Breast Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Phase 3 Completed

200 enrolled 16 charts

Breast

HER2-positive Early Breast Cancer

NCT01196390 2026-02-18

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Phase 3 Completed

203 enrolled 22 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT02947685 2026-02-12

PATINA

Phase 3 Active not recruiting

518 enrolled 15 charts

Breast

Breast Neoplasms

NCT05415215 2026-02-10

ProHer

Phase 3 Completed

346 enrolled 20 charts

Breast

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast

Breast Neoplasms

NCT03615326 2025-12-11

MK-3475-811

Phase 3 Completed

738 enrolled 22 charts 7 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 2 FDA

Breast

Breast Neoplasms

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 3 Completed

305 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02003209 2025-08-08

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Phase 3 Completed

315 enrolled 11 charts

Breast

Breast Neoplasms

NCT01772472 2025-07-22

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Phase 3 Completed

1,486 enrolled 37 charts 2 FDA

Breast

Breast Neoplasms

NCT01275677 2025-07-14

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Phase 3 Completed

3,270 enrolled 16 charts

Breast

Breast Neoplasms

NCT00769379 2025-06-12

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Phase 3 Completed

2,014 enrolled 16 charts

Breast

Carcinoma, Intraductal, Noninfiltrating

NCT00520975 2025-03-28

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase 3 Terminated

96 enrolled 16 charts

Breast

Breast Neoplasms

NCT00490139 2025-03-21

ALTTO

Phase 3 Completed

8,381 enrolled 22 charts

Breast

Breast Neoplasms

NCT00667251 2025-03-21

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Phase 3 Completed

652 enrolled 50 charts

Breast

Breast Neoplasms

NCT02492711 2025-03-17

SOPHIA

Phase 3 Completed

624 enrolled 17 charts 3 FDA

Tumor-Agnostic

Neoplasm Metastasis

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Phase 3 Completed

369 enrolled 19 charts

Breast

Breast Neoplasms

NCT01084876 2025-02-11

Compare

Phase 3 Completed

475 enrolled 25 charts

Breast

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

Phase 3 Completed

454 enrolled 28 charts

Breast

Breast Neoplasms

NCT04957212 2024-07-26

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Phase 3 Completed

214 enrolled 16 charts

Breast

HER2-positive Breast Cancer

NCT03425656 2024-06-28

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

Phase 3 Completed

108 enrolled 7 charts

Breast

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

Phase 3 Completed

500 enrolled 28 charts 3 FDA

Breast

Breast Neoplasms

NCT03084237 2024-05-17

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

Phase 3 Completed

652 enrolled 15 charts

Breast

Breast Neoplasms

NCT01120184 2024-03-04

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Phase 3 Completed

1,095 enrolled 46 charts

Breast

Breast Neoplasms

NCT03262935 2023-10-19

TULIP

Phase 3 Completed

437 enrolled 17 charts

Breast

Breast Neoplasms

NCT02586025 2023-05-22

PEONY

Phase 3 Completed

329 enrolled 33 charts

Breast

Breast Neoplasms

NCT00272987 2023-04-28

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Phase 3 Terminated

63 enrolled 22 charts

Breast

Breast Neoplasms

NCT01875367 2023-04-05

ChangHER-SC

Phase 3 Completed

166 enrolled 24 charts

Breast

Breast Neoplasms

NCT04109391 2022-10-26

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Phase 3 Completed

338 enrolled 15 charts

Breast

Breast Neoplasms

NCT02162667 2022-08-03

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

Phase 3 Completed

562 enrolled 15 charts

Breast

HER2-positive Carcinoma of Breast

NCT01966471 2022-06-14

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Phase 3 Completed

1,846 enrolled 19 charts

Breast

Breast Neoplasms

NCT02472964 2022-02-14

HERiTAge

Phase 3 Completed

500 enrolled 9 charts

Breast

Breast Neoplasms

NCT03556358 2022-01-14

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

Phase 3 Completed

809 enrolled 14 charts

Breast

Breast Neoplasms

NCT02896855 2021-12-16

PUFFIN

Phase 3 Completed

243 enrolled 23 charts

Breast

Breast Neoplasms

NCT00553358 2021-09-21

Neo ALTTO

Phase 3 Completed

455 enrolled 34 charts

Breast

Breast Neoplasms, Osteitis Deformans

NCT01989676 2021-07-06

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Phase 3 Completed

707 enrolled 20 charts

Breast

Breast Neoplasms

NCT01566721 2021-04-27

SafeHER

Phase 3 Completed

2,577 enrolled 16 charts 2 FDA

Breast

Breast Neoplasms

NCT01774786 2020-12-30

JACOB

Phase 3 Completed

780 enrolled 24 charts

Gastrointestinal

Stomach Neoplasms

NCT01940497 2020-11-03

SCHEARLY

Phase 3 Completed

240 enrolled 14 charts

Breast

Breast Neoplasms

NCT01572038 2020-09-25

PERUSE

Phase 3 Completed

1,436 enrolled 53 charts

Breast

Breast Neoplasms

NCT00567190 2019-12-13

CLEOPATRA

Phase 3 Completed

808 enrolled 29 charts

Breast

Breast Neoplasms

NCT01926886 2019-09-18

A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)

Phase 3 Completed

102 enrolled 8 charts

Breast

Breast Neoplasms

NCT01901146 2019-08-07

Lilac

Phase 3 Completed

725 enrolled 18 charts

Breast

Breast Neoplasms

NCT01125566 2019-07-18

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Phase 3 Completed

508 enrolled 13 charts

Breast

Breast Neoplasms

NCT02131064 2019-07-02

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Phase 3 Completed

444 enrolled 27 charts

Breast

Breast Neoplasms

NCT00968968 2019-06-10

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Phase 3 Terminated

37 enrolled 11 charts

Tumor-Agnostic

Carcinoma, Neoplasms

NCT00820222 2019-04-02

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Phase 3 Completed

540 enrolled 18 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00513292 2019-01-23

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Phase 3 Completed

280 enrolled 12 charts

Breast

Breast Neoplasms

NCT00876395 2018-12-19

BOLERO-1

Phase 3 Completed

719 enrolled 25 charts

Breast

Breast Neoplasms, Neoplasm Metastasis